Importantly, HIF-1α levels correlated with prognosis, as glioma patients expressing higher levels of HIF-1α showed a median survival 10 months shorter than patients expressing lower levels of HIF-1α (15.6 vs 25.6 months, respectively; Fig. 2C). This evidence concerns the gene HIF1A and central nervous system cancer.